December 4, 2020

The Niche

Knoepfler lab stem cell blog

Demcizumab

2 min read

Where do things stand with some players in the for-profit world of stem cell and cellular medicine companies? Here are a few brief news items with quick analysis. Mesoblast is dominating the news of late. Mesoblast reported good news from its Phase II safety trial for its mesenchymal progenitor cell (MPC) product in patients with Type II Diabetes. There were no treatment-related adverse outcomes and as a bonus there were hints of efficacy. Osiris Going in New Direction. Cellular medicine company Osiris has been in …Read More